Market Overview

Otonomy Rips 90% After Meniere's Disease Drug Achieves Primary Endpoint

Otonomy Rips 90% After Meniere's Disease Drug Achieves Primary Endpoint
Related OTIC
The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt
Report: Exploring Fundamental Drivers Behind St. ... (GuruFocus)

Otonomy Inc (NASDAQ: OTIC), a biopharmaceutical company that focuses on therapies related to diseases and disorders of the ear, reported its third-quarter results and announced an encouraging update to a phase 2 trial.

What You Need To Know

Otonomy lost 69 cents in its third quarter on revenue of $282,000; Wall Street analysts were expecting the company to lose 76 cents per share on revenue of $330,000.

The company ended the quarter with cash, cash equivalents, and short-term investments of $134.3 million versus $196.4 million as of the end of 2016. During the quarter, R&D expenses were $10.8 million versus $15.9 million in the same quarter a year ago.

In conjunction with the earnings report, Otonomy announced that its AVERTS-2 trial in patients with Meniere's Disease achieved its primary endpoint. The company's therapy called OTIVIDEX demonstrated clinically significant treatment benefit for patients.

Related Link: The Market In 5 Minutes: Adidas, Jobless Claims, And More

Why It's Important

The successful results of Otonomy's AVERTS-2 trial marks an "important milestone for the company and renews our excitement and commitment to continuing the registration program for OTIVIDEX," CEO David Weber, Ph.D., said in a press release.

The company now plans to proceed with a Phase 3 trial of AVERTS and will be meeting with the U.S. Food and Drug Administration in the first quarter of 2018 to discuss and review clinical requirements.

In addition, management will undertake a pipeline review and prioritization to present a development plan for multiple clinical and preclinical programs in the first quarter of next year.

"We believe that the continuation of OTIVIDEX development for Ménière's disease and the advancement of our other programs targeting important unmet medical needs including hearing loss and tinnitus provide an attractive path forward for Otonomy," Weber said. "We intend to use our strong balance sheet, supported by our recent cost reduction actions, to achieve value creation milestones in the development of our pipeline."

Stock Reaction

Shares of Otonomy were trading higher by around 112 percent Thursday morning at $5.95, but are still lower by more than 60 percent since the start of 2017 and well-off its 52-week high of $21.15.

Posted-In: ear Ear Disease OTIVIDEXEarnings News Health Care Movers General Best of Benzinga


Related Articles (OTIC)

View Comments and Join the Discussion!

The 20 Best Business Books Of 2017, According To Amazon

Gold Forecast: $1300 A Done Deal?